Novartis touts new T-cell therapy data in race for FDA approval – Reuters
Reuters |
Novartis touts new T–cell therapy data in race for FDA approval
Reuters Globally, there are some 183 CAR–T trials underway. In March, Novartis filed CTL019 with the U.S. Food and Drug Administration for fast-track approval in B-cell acute lymphoblastic leukemia (ALL) in young patients. The FDA has scheduled a July 12 … As Novartis preps for first CAR–T FDA AdComm, Juliet data revealedFierceBiotech Novartis posts landmark CAR–T data as head-to-head rivalry with Kite Pharma loomsEndpoints News Novartis’ CAR–T stacks up to Kite in lymphomaBioPharma Dive GlobeNewswire (press release) all 9 news articles » |
|
Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals
TheStreet.com Calithera Biosciences (CALA) was up to $16.10, a spike of 70 cents or 4.55%, after the FDA designated the company’s lead product candidate, CB-839, in combination with Novartis’ AFINITOR for Fast Track review for the treatment of metastatic renal cell … |
Science Daily |
‘Immunoswitch’ particles may be key to more-effective cancer immunotherapy
Science Daily For their study, the Johns Hopkins researchers combined two different immunotherapy strategies on humanmade nanoparticles about 1,000 times smaller in diameter than a human hair, similar to drug-delivery platforms already in use in some cancer … |
|
Application Note: CRISPR/Cas9 Genome-Wide gRNA Library for Target Identification
SelectScience This study investigates the potential differences in the RNAi and CRISPR HTGS technologies, by performing parallel dropout viability screens using module-1 human genome-wide CRISPR sgRNA library and module-1 human genome-wide RNAi shRNA … |
|
Application Note: CRISPR/Cas9 Genome-Wide gRNA Library for Target Identification
SelectScience This study investigates the potential differences in the RNAi and CRISPR HTGS technologies, by performing parallel dropout viability screens using module-1 human genome-wide CRISPR sgRNA library and module-1 human genome-wide RNAi shRNA … |